Delcath Systems delivered a strong second quarter in 2025, with total revenue more than tripling year-over-year, driven primarily by robust HEPZATO KIT sales. The company achieved net income and positive adjusted EBITDA, a significant turnaround from losses in the prior year, and reported a healthy cash position.

Delcath Systems achieved a strong start to 2025 with significant revenue growth, reaching $19.8 million, up from $3.1 million in the prior year. The company also reported its first quarter of net income of $1.1 million and positive operating cash flow, driven by the accelerating clinical adoption of HEPZATO.

Delcath Systems reported a strong third quarter with a 44% increase in revenue compared to the prior quarter, driven by HEPZATO KIT sales. The company is focusing on expanding its development pipeline and reported a solid financial position with a strong balance sheet and consistent revenue growth, putting them on the cusp of profitability.

Delcath Systems reported a significant increase in revenue for the second quarter of 2024, driven by sales of HEPZATO KIT™ and CHEMOSAT. The company is focused on expanding the adoption of HEPZATO KIT and advancing its clinical programs.

Delcath Systems reported a significant increase in total revenue for Q1 2024, reaching $3.1 million compared to $0.6 million in the same period last year. The company is focused on expanding the availability of HEPZATO and is committed to reaching 20 treating centers by the end of 2024.

Delcath Systems reported a decrease in revenue for Q3 2023, with total revenue at $0.4 million compared to $0.9 million in the prior year. The company's operating expenses increased due to research and development and commercial launch preparations. They also received FDA approval for HEPZATO KIT and raised approximately $35 million through warrant exercises.

Delcath Systems reported total revenue of $0.5 million for the second quarter ended June 30, 2023, compared to $0.8 million for the prior year period. The company's research and development expenses were $3.6 million, compared to $5.6 million in the prior year quarter. Selling, general and administrative expenses for the quarter increased to $4.8 million, compared to $4.5 million in the prior year quarter.

Delcath Systems reported preliminary Q1 2023 revenue of $0.6 million, compared to $0.4 million in Q1 2022. The company had cash, cash equivalents, and restricted cash totaling $24.3 million as of March 31, 2023, compared to $11.8 million as of March 31, 2022. They are awaiting the FDA's decision on Hepzato Kit with a PDUFA date of August 14, 2023.

Delcath Systems announced a private placement expected to provide up to $85 million in gross proceeds. The financing, led by Vivo Capital, includes an initial upfront funding of $25 million and is expected to fund the company through potential approval of HEPZATO and its commercialization.

Delcath Systems reported first quarter 2022 financial results, with a total revenue of $0.3 million, primarily from CHEMOSAT sales in Europe. The company's net loss was $8.2 million, and they are preparing to file an NDA for HEPZATO in the third quarter of 2022.

Delcath Systems reported product revenue of $522 thousand for the three months ended September 30, 2021, compared to $466 thousand for the prior year period. The company's net loss for the quarter was $7.1 million, compared to a net loss of $5.0 million for the same period in 2020. They closed a $20 million venture debt financing transaction with Avenue Venture Opportunities Fund, L.P. during the quarter.

Delcath Systems, Inc. reported an increase in product revenue for the second quarter of 2021, driven by sales of CHEMOSAT procedures in Europe. The company also announced positive efficacy results from its FOCUS Phase III trial of HEPZATO™ KIT and entered into a debt facility with Avenue Venture Opportunities Fund, L.P.

Delcath Systems, Inc. reported a revenue increase to $0.4 million for the first quarter of 2021, compared to $0.3 million in the prior year. However, the company recorded a net loss of $6.8 million, a shift from the net income of $7.9 million in the same period of 2020. The company's cash and cash equivalents totaled $26.7 million.

Delcath Systems, Inc. reported a decrease in product revenue for Q4 2020, with $379 thousand compared to $398 thousand in the prior year period. Despite the revenue decrease, the company highlighted positive preliminary results from the FOCUS Clinical Trial and strengthened its executive team. The company experienced a net loss of $7.0 million, compared to a net income of $12.5 million for the same period in 2019.

Delcath Systems, Inc. announced financial results for the quarter ended June 30, 2020. The company completed a $22 million public offering and uplisted to the NASDAQ Capital Market. Product revenue was $262 thousand, and the net loss was $4.3 million.